0
Clinical Investigations: ASTHMA |

A Randomized, Placebo-Controlled Study To Evaluate the Role of Salmeterol in the In-Hospital Management of Asthma*

Jay I. Peters, MD, FCCP; David C. Shelledy, PhD, RRT; Arthur P. Jones Jr., EdD, RRT; Robert W. Lawson, MS, RRT; Charles P. Davis, MD, PhD; Terry S. LeGrand, PhD, RRT
Author and Funding Information

*From the Department of Medicine (Dr. Peters), Division of Pulmonary Diseases/Critical Care Medicine, The Department of Respiratory Care (Drs. Shelledy, Jones, and LeGrand, and Mr. Lawson), and The Department of Surgery (Dr. Davis), The University of Texas Health Science Center at San Antonio, TX.

Correspondence to: Jay I. Peters, MD, FCCP, Pulmonary Disease Section (111E), South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Division, 7400 Merton Minter Blvd, San Antonio, TX 78284; e-mail: peters@uthscsa.edu



Chest. 2000;118(2):313-320. doi:10.1378/chest.118.2.313
Text Size: A A A
Published online

Study objectives: To assess the safety and efficacy of salmeterol xinafoate as an adjunct to conventional therapy for the in-hospital management of acute asthma.

Design: A prospective, double-blind, randomized placebo-controlled trial.

Setting: Medical wards of a large university-based hospital.

Patients: Forty-three patients admitted for an acute exacerbation of asthma.

Interventions: Salmeterol (42 μg) or two puffs of placebo every 12 h in addition to standard therapy (short-acting β-agonists, corticosteroids, and anticholinergic agents).

Results: No clinically adverse effects were seen with the addition of salmeterol to conventional therapy. After salmeterol, there was no difference in pulse, respiratory rate, oxygen saturation by pulse oximetry, severity of symptoms, or dyspnea score. Patients receiving salmeterol had greater FEV1 percent improvements than the placebo group at 12, 24, 36, and 48 h. These findings were not statistically significant. By paired Student’s t tests, there were significant improvements in FEV1 (p = 0.03) and FVC (p = 0.03) in the salmeterol group after 48 h of treatment with no comparable improvement in the placebo group. In a subgroup analysis of patients with an initial FEV1 ≤ 1.5 L, the absolute FEV1 percent improvement for salmeterol vs placebo was 51% vs 16% at 24 h and 54% vs 40% at 48 h. The relative FEV1 percent improvement for salmeterol vs placebo was 17% vs 8% at 24 h and 18% vs 14% at 48 h.

Conclusion: The addition of salmeterol to conventional therapy is safe and may benefit hospitalized patients with asthma. Further studies are needed to clarify its role in the treatment of acute exacerbation of asthma.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543